eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, is an activator of anti-tumor immune response

被引：0
|
作者：
Webster, Kevin [1 ]
Sharma, Rajesh [1 ]
Goel, Vikas [1 ]
Stumpf, Craig [1 ]
Stauton, Jocelyn [1 ]
Thompson, Peggy [1 ]
Chiang, Gary [1 ]
Xu, Yichen [2 ]
Jin, Hyun Yong [2 ]
Ruggero, Davide [2 ]
机构：
[1] eFFECTOR Therapeut, San Diego, CA USA
[2] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P368
引用
收藏
页数：2
相关论文
共 50 条
  • [21] AB801 is a highly potent and selective AXL kinase inhibitor that demonstrates significant anti-tumor activity
    Paprcka, Susan Lee
    Goshayeshi, Armon
    Liu, Suan
    Flores, Ruben
    Rocha, Lauren
    Leslie, Jhansi L.
    Miles, Dillon H.
    Foley, Corinne N.
    Qu, Shiwei
    Lamani, Manjunath
    Paladugu, Srinivas
    Huang, Hsin-Ting
    Tribewal, Nidhi
    Chen, Ada
    Kulusich, Joseph
    Garrido-Shaqfeh, Stefan
    Fabila, Patricia
    Jafri, Salema
    Devarajan, Anuja
    Fernandez-Salas, Ester
    CANCER RESEARCH, 2023, 83 (07)
  • [22] Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response
    Works, Melissa
    Bennett, Mark
    Chen, Jason
    Emberley, Ethan
    Huang, Tony
    Janes, Julie
    Li, Weiqun
    Mackinnon, Andy
    Marguier, Gisele
    Neou, Silinda
    Pan, Alison
    Parlati, Francesco
    Rodriguez, Mirna
    Steggerda, Susanne
    Wang, Tracy
    Zhang, Jing
    Zhang, Winter
    Gross, Matthew
    CANCER RESEARCH, 2016, 76
  • [23] Discovery of a potent and selective PARP1 inhibitor and trapper with anti-tumor activities in HRD tumors
    Gao, Mingming
    Li, Zhentian
    Fan, Qipeng
    Pan, Jun
    Bai, Yu
    Zhang, Hewen
    Li, Yu
    Wu, Yongzhong
    Liu, Phillip C. C.
    Wu, Liangxing
    Yao, Wenqing
    Wang, Hui
    CANCER RESEARCH, 2023, 83 (07)
  • [24] BMS-387032: A selective CDK2 inhibitor with potent anti-tumor activity.
    Misra, RN
    Xiao, HY
    Kim, KS
    Lu, SF
    Han, WC
    Rawlins, DB
    Shan, WF
    Ahmed, SZ
    Qian, L
    Chen, BC
    Zhao, RL
    Bednarz, MS
    Bursuker, I
    Kellar, KA
    Mulheron, JG
    Batorsky, R
    Roongta, U
    Sacks, JS
    Tokarski, JS
    Lee, FY
    Bol, DK
    Kamath, A
    Humphreys, WG
    Marathe, P
    Hunt, JT
    Pavletich, NP
    Kimball, SD
    Webster, KR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U176 - U176
  • [25] RGT-264 a highly potent, selective and orally bioavailable HPK1 (MAP4K1) inhibitor augments immune activation and anti-tumor immunity
    Xiao, F.
    Liu, H.
    Wu, L.
    Feng, S.
    Liu, Y.
    Xiao, H.
    Li, H.
    Huang, W.
    Ren, X.
    Ren, B.
    Yao, L.
    Lin, J.
    Zhong, W.
    Xie, Z.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S172 - S173
  • [26] Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies
    Thompson, Peggy A.
    Eam, Boreth
    Young, Nathan P.
    Fish, Sarah
    Chen, Joan
    Barrera, Maria
    Howard, Haleigh
    Parra, Ana
    Molter, Jolene
    Staunton, Jocelyn
    Hung, Ivy N. J.
    Parker, Greg S.
    Chiang, Gary G.
    Wegerski, Chris J.
    Nevarez, Andres
    Clarine, Jeff
    Sperry, Sam
    Xiang, Alan
    Tran, Chinh
    Nilewski, Christian
    Packard, Garrick K.
    Michels, Theodore
    Sprengeler, Paul A.
    Ernst, Justin T.
    Reich, Siegfried H.
    Webster, Kevin R.
    BLOOD, 2017, 130
  • [27] HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities
    Chen, Xu-Xing
    Shen, Qian-Qian
    Zhao, Zhao
    Fang, Yan-Fen
    Yang, Jun-Yu
    Gao, Ying-Lei
    Liu, Lei
    Zhang, Yixiang
    Chen, Yi
    Li, Leping
    CANCER RESEARCH, 2022, 82 (12)
  • [28] Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers
    Thompson, Peggy A.
    Young, Nathan P.
    Gerson-Gurwitz, Adina
    Eam, Boreth
    Goel, Vikas
    Stumpf, Craig R.
    Chen, Joan
    Parker, Gregory S.
    Fish, Sarah
    Barrera, Maria
    Sung, Eric
    Staunton, Jocelyn
    Chiang, Gary G.
    Webster, Kevin R.
    CANCER RESEARCH, 2020, 80 (16)
  • [29] Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response
    Gupta, Shishir Kumar
    Yadav, Pavan Kumar
    Tiwari, A. K.
    Gandham, Ravi Kumar
    Sahoo, A. P.
    TUMOR BIOLOGY, 2016, 37 (09) : 12089 - 12102
  • [30] Promoting an anti-tumor immune environment with a novel, exquisitely selective CSF1R inhibitor
    Suzuki, Erika
    Kovacs, Jeffrey J.
    Spencer, Nakia D.
    Sonal, Sonal
    Feng, Ningping
    Harris, Angela L.
    Mullinax, Robert A.
    Zuniga, Andy M.
    Johnson, Sarah B.
    Mahendra, Mikhila
    Khor, Tin Oo
    Mseeh, Faika
    Liu, Zhen
    Burke, Jason P.
    Mikule, Keith
    Tremblay, Martin
    Heffernan, Timothy P.
    Jones, Philip
    Czako, Barbara
    Marszalek, Joseph R.
    CANCER RESEARCH, 2018, 78 (13)
12345